NCT05503888View on ClinicalTrials.gov

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2027

Conditions
Relapsed or Advanced Non-small Cell Lung Cancer
Interventions
DRUG

Almonertinib combined with SHR-1701

"Phase Ⅰb/Phase Ⅱ：~SHR-1701: injection, intravenous infusion~Almonertinib: tablets, oral"

DRUG

Almonertinib

"Phase Ⅱ:~Almonertinib: tablets, oral"

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT05503888 - Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter